FDA
label_change
· 2018-07-05
FDA Approved: FASLODEX — Supplemental Application (AstraZeneca Pharmaceuticals LP)
Summary
FDA approved a supplemental application for FASLODEX (fulvestrant) submitted by AstraZeneca Pharmaceuticals LP. The decision involves changes to the drug's labe…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for FASLODEX (FULVESTRANT)